Eris Lifesciences inks deal with Natco Pharma for weight-loss drug semaglutide
The collaboration will leverage Eris’s commercial presence in the diabetes segment and Natco’s manufacturing and regulatory prowess in complex formulations
The collaboration will leverage Eris’s commercial presence in the diabetes segment and Natco’s manufacturing and regulatory prowess in complex formulations
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
